Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2QO5J
|
|||
| Drug Name |
BMS-986012
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Small-cell lung cancer [ICD-11: 2C25.Y] | Phase 2 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 2 | [2] | ||
| Company |
Bristol-Myers Squibb
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fucosyl GM1 (FucGM1) | Target Info | Inhibitor | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04702880) A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04702880) A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer. U.S. National Institutes of Health. | |||
| REF 3 | A Novel, Fully Human Anti-fucosyl-GM1 Antibody Demonstrates Potent In Vitro and In Vivo Antitumor Activity in Preclinical Models of Small Cell Lung Cancer. Clin Cancer Res. 2018 Oct 15;24(20):5178-5189. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.